Objective： Peripheral T-cell lymphomas （PTCLs） confer dismal prognosis and no consensus has been established on the role of allogeneic hematopoietic stem cell transplantation （allo-HSCT） due to its rarity and het...Objective： Peripheral T-cell lymphomas （PTCLs） confer dismal prognosis and no consensus has been established on the role of allogeneic hematopoietic stem cell transplantation （allo-HSCT） due to its rarity and heterogeneity. The purpose was to review key points ofallo-HSCT for PTCLs, including indication, times of transplantation, conditioning regimen, graft versus host disease prophylaxis, and treatment of relapse.Data Sources： A comprehensive search in PubMed and Cochrane up to February 28, 2018, with the keywords ＂Peripheral＂, ＂T＂, ＂Lymphoma＂, and ＂Transplantation＂ was done. Study Selection： Relevant articles including HSCT for PTCLs were carefully reviewed. Results： Promising data have been reported from advances in transplant technology and more and more PTCLs patients with poor prognosis could benefit from allo-HSCT. Conclusion： Allo-HSCT is a useful choice for patients with refractory/relapsed PTCLs or high-risk new diagnosed PTCLs.展开更多
文摘Objective： Peripheral T-cell lymphomas （PTCLs） confer dismal prognosis and no consensus has been established on the role of allogeneic hematopoietic stem cell transplantation （allo-HSCT） due to its rarity and heterogeneity. The purpose was to review key points ofallo-HSCT for PTCLs, including indication, times of transplantation, conditioning regimen, graft versus host disease prophylaxis, and treatment of relapse.Data Sources： A comprehensive search in PubMed and Cochrane up to February 28, 2018, with the keywords ＂Peripheral＂, ＂T＂, ＂Lymphoma＂, and ＂Transplantation＂ was done. Study Selection： Relevant articles including HSCT for PTCLs were carefully reviewed. Results： Promising data have been reported from advances in transplant technology and more and more PTCLs patients with poor prognosis could benefit from allo-HSCT. Conclusion： Allo-HSCT is a useful choice for patients with refractory/relapsed PTCLs or high-risk new diagnosed PTCLs.
